COPPER PRICE RISK: Credit Suisse analyst Curt Woodworth downgraded Freeport McMoRan ($FCX) to Underperform from Neutral with a $29 price target. Copper prices are more a reflection of future inflation expectations than a real-time gauge of the health of the global economy, Woodworth tells investors in a research note. The analyst is concerned that the market is "overly bullish" on the medium term demand uptake from electric vehicles and renewables. He does not foresee a "decoupling event" in copper prices to historical macro variables until 2025-2027 "at the earliest." As these industries evolve and scale, copper intensity "could be far lower than expected owing to miniaturization and new technologies, says Woodworth. The analyst sees risk to copper prices as inflation fears ease and China demand slows.'MIXED BAG' SCENARIO: Wedbush analyst Laura Chico downgraded Apellis ($APLS) to Neutral from Outperform with a price target of $39, down from $71. The readout of the company's DERBY/OAKS studies ended in a "mixed bag" scenario with OAKS meeting the primary endpoint and DERBY missing, Chico tells investors in a research note. The key question going forward centers on pegcetacoplan's potential approvability, and Chico expects that the regulatory overhang will remain in place with additional data still ~1 year away.Separately, JPMorgan analyst Anupam Rama lowered the firm's price target on Apellis to $57 from $101 and keeps an Overweight rating on the shares. The analyst also removed the shares from JPMorgan's U.S. Equity Analyst Focus List. The top-line results from the DEBY / OAKS trials into the "previously outlined mixed scenario," Rama tells investors in a research note. While disappointing, the totality of the data across DERBY / OAKS / FILLY trials should ultimately get pegcetacoplan approved, says the analyst. He believes pegcetacoplan "can still be a very big drug even with a very conservative view."SUNRUN, FIRST SOLAR INITIATED: Needham analyst Vik Bagri initiated coverage of Sunrun ($RUN) with a Buy rating and $75 price target. Sunrun is "the leader in the crowded U.S. residential solar industry" with about 15% share, which Bagri identifies as almost twice that of its closest competitor. He thinks the industry can keep growing at a fast pace due to EV adoption and sees the shares trading "at a compelling entry point" with Sunrun down over 50% from its highs, he added.Needham's Bagri also initiated coverage of First Solar with a Hold rating. The company is the only top-10 US-based solar module manufacturer with differentiated CdTe technology as its competitive advances led to increase in backlog this year, the analyst tells investors in a research note. Bagri adds however that because of higher freight costs and a projected 11% degradation in average selling price next year, First Solar's margins should narrow.'EROSION' OF SHARE: Cowen analyst Brian Holland initiated coverage of Beyond Meat ($BYND) with a Market Perform rating and $124 price target. The analyst thinks ongoing U.S. retail market share and gross margin "erosion" could weigh on the shares. Longer term, however, Beyond Meat's "vast international whitespace" and cost down initiatives could drive both its revenues and profits, Holland tells investors in a research note. The analyst says that while plant based meat "cooks up a compelling sustainability narrative," there are factors limiting penetration as meat consumption is growing.LULULEMON PRICE TARGET RAISED: Argus analyst John Staszak raised the firm's price target on Lululemon ($LULU) to $500 from $416 and keeps a Buy rating on the shares after its Q2 earnings beat and guidance raise. The analyst is positive on the company's "strong brand" and "growing" direct-to-consumer sales, which should drive higher margins over the next several years. Staszak is also raising his Lululemon FY22 EPS view by 70c to $7.50 and FY23 view by 90c to $9.40. CIGNA DOUBLE DOWNGRADE: BofA analyst Kevin Fischbeck downgraded Cigna ($CI) to Underperform from Buy with a price target of $225, down from $240. While the company has now integrated Express Scripts successfully, de-levered, and sold off underperforming units, the growth outlook from here is "less clear" and he sees lower visibility in its earnings trajectory over the next couple of years, Fischbeck tells investors. Cigna's business mix has the slowest end-market growth of any MCO he covers, the analyst added. In addition, Cowen analyst Gary Taylor assumed coverage of Cigna and downgraded the stock to Market Perform from Outperform with a price target of $235, down from $300.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .